Results 171 to 180 of about 43,229 (277)

Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B. [PDF]

World J Gastroenterol
Fu YC, Li J, Wang JY, Zhang YW, Yan F, Chen J, Du Q, Yang C, Liang J, Ye Q, Xiang HL.   +10 more
europepmc   +1 more source

Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients [PDF]

, 2012
Jian Chen, Jian Shi, Wei‐Fen Xie, Xin Zeng, Yong Lin   +4 more
openalex   +1 more source

Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B. [PDF]

Front Immunol, 2023
Huang L, Zhang H, Kang X, Chen Z, Wang L, Zeng Y.   +5 more
europepmc   +1 more source

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks [PDF]

, 2011
Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, G Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O. Boecher, Ewert Schulte‐Frohlinde, R Prinzing, Eva Herrmann, Stefan Zeuzem, Thomas Berg   +15 more
openalex   +1 more source

Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection. [PDF]

Drug Des Devel Ther
Zhang Y, Li Y, Lian JQ, Kang W.
europepmc   +1 more source

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 [PDF]

, 2010
Antonio D’Avolio, Alessia Ciancio, Marco Siccardi, Lorena Baietto, Marco Simiele, Giuseppe Cariti, Andrea Calcagno, Antonina Smedile, Jessica Cusato, Stefano Bonora, Mario Rizzetto, Giovanni Di Perri   +11 more
openalex   +1 more source

P81 Psychiatric side effects of antiviral therapy with pegylated interferon and ribavirin are associated with poor response in children with chronic hepatitis C

, 2010
Ivana Carey, Carmine M. Pariante, Sanjay Bansal, Prem S. Subramaniam, Sarah Tizzard, Diego Vergani, Giorgina Mieli‐Vergani   +6 more
openalex   +1 more source

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C [PDF]

, 2011
Jae Hee Lim, Yun Nah Lee, Young Seok Kim, Sang Gyune Kim, Seungwon Jeong, Jae Young Jang, Hong Soo Kim, Sae Hwan Lee, Tae Kwann Park   +8 more
openalex   +1 more source

Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection. [PDF]

J Viral Hepat
Hardtke S, Yurdaydin C, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Port K, Manns MP, Cornberg M, Kahlhöfer J, Wedemeyer H.   +15 more
europepmc   +1 more source

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

, 2013
Antonia Busse, Jérôme Rapion, Alberto Fusi, Stefan Suciu, Anika Nonnenmacher, Mario Santinami, Wim H.J. Kruit, Alessandro Testori, Cornelis J.A. Punt, Angus Dalgleish, Alan Spatz, Alexander Eggermont, Ulrich Keilholz   +12 more
openalex   +2 more sources